Emerald Advisers’s Alder Biopharmaceuticals ALDR Stock Holding History

Emerald Advisers’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,358,056	Closed	-$21.5M	–	280
2018 Q2	$21.5M	Sell	1,358,056 -193,817	-12%	-$2.95M	0.81%	50
2018 Q1	$19.7M	Sell	1,551,873 -178,155	-10%	-$2.58M	0.79%	47
2017 Q4	$19.8M	Buy	1,730,028 +151,551	+10%	+$1.69M	0.76%	50
2017 Q3	$19.3M	Buy	1,578,477 +384,805	+32%	+$4.01M	0.79%	49
2017 Q2	$13.7M	Buy	1,193,672 +591,840	+98%	+$10.9M	0.57%	73
2017 Q1	$12.5M	Sell	601,832 -11,400	-2%	-$252K	0.51%	81
2016 Q4	$12.8M	Buy	613,232 +202,817	+49%	+$5.27M	0.54%	76
2016 Q3	$13.4M	Buy	410,415 +174,222	+74%	+$5.31M	0.6%	61
2016 Q2	$5.9M	Buy	+236,193	New	+$6.39M	0.28%	116

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Emerald Advisers's ALDR Position: Q3 2018 in Review

Emerald Advisers sold out of Alder Biopharmaceuticals (ALDR) in Q3 2018, closing a stake of 1,358,056 shares — an estimated $21.5M sold.

Emerald Advisers first reported a position in ALDR in Q2 2016 and held it in 9 quarters. The position peaked at $21.5M in Q2 2018. 127 funds tracked by Wall St. Rank hold ALDR as of Q3 2018.

Emerald Advisers reported no remaining Alder Biopharmaceuticals position as of Q3 2018 after selling out during the quarter.
Emerald Advisers sold 1,358,056 Alder Biopharmaceuticals shares in Q3 2018, an estimated $21.5M.
Emerald Advisers first reported a position in Alder Biopharmaceuticals in Q2 2016 and held it in 9 quarters.
Emerald Advisers's Alder Biopharmaceuticals position peaked at $21.5M in Q2 2018.
127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2018.

Based on Emerald Advisers's 13F filing for Q3 2018, filed 31 Oct 2018.